Repositioning Candidate Details
| Candidate ID: | R0889 |
| Source ID: | DB05869 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Ethyl pyruvate |
| Synonyms: | 2-oxopropanoic acid ethyl ester; 2-oxopropionic acid ethyl ester; Ethyl 2-oxopropanoate; Ethyl 2-oxopropionate; Ethyl methylglyoxylate; Pyruvic acid ethyl ester; Pyruvic acid, ethyl ester |
| Molecular Formula: | C5H8O3 |
| SMILES: | CCOC(=O)C(C)=O |
| Structure: |
|
| DrugBank Description: | CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia. |
| CAS Number: | 617-35-6 |
| Molecular Weight: | 116.1152 |
| DrugBank Indication: | Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | CTI-01 inhibits the systemic release of cytokines, such as TNF-alpha and HMGB1, which promote the body's inflammatory response. The over-expression of these cytokines has been linked to diseases that occur in critical care settings, such as severe organ damage following cardiopulmonary bypass (CPB) and post-operative ileus following abdominal surgery. |
| Targets: | Tumor necrosis factor; High mobility group protein B1 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|